Tags: Sanofi | Aventis | Genzyme

Sanofi-Aventis Unveils Bid for Genzyme

Sunday, 29 Aug 2010 06:17 PM

French drug giant Sanofi-Aventis SA announced that it has submitted a non-binding proposal to acquire American biotech firm Genzyme Corp. — in an all-cash transaction valued at approximately $18.5 billion.

Under the terms of the proposed acquisition, Genzyme shareholders would receive $69 per Genzyme share in cash, representing a 38 percent premium over Genzyme's unaffected share price of $49.86 on July 1.

The move Sunday came nearly two months after rumors first surfaced on July 2 that Sanofi was looking to buy an American drugmaker in a bid to help replace revenue being lost to worsening generic competition. Since then, Sanofi unexpectedly got generic competition on July 23 for its blockbuster injected anticlotting drug, Lovenox, which brought Sanofi $3.9 billion last year.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Companies
French drug giant Sanofi-Aventis SA announced that it has submitted a non-binding proposal to acquire American biotech firm Genzyme Corp. in an all-cash transaction valued at approximately $18.5 billion.Under the terms of the proposed acquisition, Genzyme shareholders...
Sanofi,Aventis,Genzyme
121
2010-17-29
Sunday, 29 Aug 2010 06:17 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved